CL2019000573A1 - Composiciones para comprimidos. - Google Patents

Composiciones para comprimidos.

Info

Publication number
CL2019000573A1
CL2019000573A1 CL2019000573A CL2019000573A CL2019000573A1 CL 2019000573 A1 CL2019000573 A1 CL 2019000573A1 CL 2019000573 A CL2019000573 A CL 2019000573A CL 2019000573 A CL2019000573 A CL 2019000573A CL 2019000573 A1 CL2019000573 A1 CL 2019000573A1
Authority
CL
Chile
Prior art keywords
tablets
compositions
trifluorometil
piridin
amino
Prior art date
Application number
CL2019000573A
Other languages
English (en)
Inventor
Chong-Hui Gu
Sreenivas S Bhat
Scott Burnside
Darshan Parikh
Syed Altaf
Original Assignee
Celgene Corp
Agios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp, Agios Pharmaceuticals Inc filed Critical Celgene Corp
Publication of CL2019000573A1 publication Critical patent/CL2019000573A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

EN LA PRESENTE SE PROPORCIONA UN COMPRIMIDO QUE COMPRENDE 2-METIL-1-[(4-[6-(TRIFLUOROMETIL)PIRIDIN-2-IL]-6-{[2-(TRIFLUOROMETIL) PIRIDIN-4-IL]AMINO}-1,3,5-TRIAZIN-2-IL)AMINO]PROPAN-2-OL O UNA SAL FARMACÉUTICAMENTE ACEPTABLE DE ESTE.
CL2019000573A 2016-09-07 2019-03-06 Composiciones para comprimidos. CL2019000573A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662384643P 2016-09-07 2016-09-07
US201762535162P 2017-07-20 2017-07-20

Publications (1)

Publication Number Publication Date
CL2019000573A1 true CL2019000573A1 (es) 2019-07-19

Family

ID=59895401

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019000573A CL2019000573A1 (es) 2016-09-07 2019-03-06 Composiciones para comprimidos.

Country Status (17)

Country Link
US (2) US11389454B2 (es)
EP (1) EP3509570A1 (es)
JP (2) JP2019529534A (es)
KR (1) KR102498693B1 (es)
CN (1) CN109715143A (es)
AU (1) AU2017324844B2 (es)
BR (1) BR112019004356A2 (es)
CA (1) CA3036053A1 (es)
CL (1) CL2019000573A1 (es)
CO (1) CO2019002092A2 (es)
EC (1) ECSP19015828A (es)
IL (1) IL265126B2 (es)
MX (1) MX2019002697A (es)
NZ (1) NZ751112A (es)
SG (1) SG11201901873PA (es)
WO (1) WO2018048847A1 (es)
ZA (1) ZA201901321B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3253746A1 (en) 2015-02-04 2017-12-13 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
BR112019004356A2 (pt) * 2016-09-07 2019-05-28 Agios Pharmaceuticals Inc composições de comprimido
WO2020092915A1 (en) * 2018-11-02 2020-05-07 Celgene Corporation Solid dispersions for treatment of cancer
WO2020092906A1 (en) * 2018-11-02 2020-05-07 Celgene Corporation Co-crystals of 2-methyl-1 -[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl) pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol, compositions and methods of use thereof
WO2020092894A1 (en) 2018-11-02 2020-05-07 Celgene Corporation Solid forms of 2-methyl-1-[(4-[6-(trifluoromethyl) pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl) amino]propan-2-ol
WO2020239759A1 (en) * 2019-05-27 2020-12-03 Sandoz Ag Amorphous enasidenib in a stabilized form
EP4058028A1 (en) * 2019-11-14 2022-09-21 Celgene Corporation Pediatric formulations for treatment of cancer
TW202317120A (zh) * 2021-06-23 2023-05-01 美商纜圖藥品公司 表皮生長因子受體抑制劑之醫藥組合物
WO2024008138A1 (zh) * 2022-07-07 2024-01-11 正大天晴药业集团股份有限公司 1,3,5-三嗪衍生物的药物组合

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW430561B (en) * 1995-12-20 2001-04-21 Gea Farmaceutisk Fabrik As Rapid release tablet composition comprising tolfenamic acid or a pharmaceutically acceptable salt thereof as active ingredient and a method of preparing such tablet
AR016827A1 (es) * 1997-08-22 2001-08-01 Smithkline Beecham Corp PROCEDIMIENTO PARA LA PREPARACIoN DE UNA TABLETA FARMACÉUTICA
WO2003007916A1 (en) * 2001-07-17 2003-01-30 Teva Pharmaceutical Industries Ltd. Dosage forms for immediate gastric release of a calcium transport stimulator coupled with delayed gastric release of a bis-phosphonate
US20070010478A1 (en) * 2005-07-06 2007-01-11 Branimir Sikic Zosuquidar, daunorubicin, and cytarabine for the treatment of cancer
CN103893140B (zh) * 2009-11-09 2016-06-01 惠氏有限责任公司 来那替尼马来酸盐的片剂制剂
BR112013004443A8 (pt) * 2010-08-23 2018-01-02 Vertex Pharma composições farmacêuticas de (r)-1-(2,2-difluorbenzo[d] [1,3]dioxol-5-il)-n-(1-(2,3-di-hidróxipropil)-6-flúor-2-(1-hidróxi-2-metilpropan-2-il)-1h-indol-5-il)ciclopropano carboxamida e administração das mesmas
DK2800743T3 (en) 2012-01-06 2018-06-14 Agios Pharmaceuticals Inc THERAPEUTIC ACTIVE RELATIONS AND PROCEDURES FOR USE THEREOF
BR112016000489A8 (pt) 2013-07-11 2020-01-07 Agios Pharmaceuticals Inc composto, composição farmacêutica que o compreende, uso da composição e métodos para fabricar compostos
WO2015018060A1 (en) 2013-08-09 2015-02-12 Agios Pharmaceuticals, Inc. Crystalline forms of therapeutically active compounds and use thereof
SG10201709187TA (en) * 2013-08-02 2017-12-28 Agios Pharmaceuticals Inc Therapeutically active compounds and their methods of use
KR102316886B1 (ko) * 2013-08-02 2021-10-19 아지오스 파마슈티컬스 아이엔씨. 치료학적 활성 화합물 및 이의 사용방법
JP2017529382A (ja) 2014-09-29 2017-10-05 アギオス ファーマシューティカルス，インコーポレーテッド 治療活性を有する化合物及びその使用方法
EP3253746A1 (en) 2015-02-04 2017-12-13 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
KR20180014778A (ko) * 2015-06-03 2018-02-09 트리아스텍 인코포레이티드 제형 및 이의 용도
CA2993615A1 (en) 2015-08-05 2017-02-09 Agios Pharmaceuticals, Inc. Methods of preparing 6-(aryl or heteroaryl)-1,3,5-triazine-2,4-diols and 6-(aryl or heteroaryl)-1,3,5-triazine-2,4-diamines
WO2017066599A1 (en) 2015-10-15 2017-04-20 Agios Pharmaceuticals, Inc. Combination therapy for treating malignancies
AU2016340098B2 (en) 2015-10-15 2022-06-02 Celgene Corporation Combination therapy for treating malignancies
IL299563A (en) 2015-12-04 2023-02-01 Agios Pharmaceuticals Inc Methods for the treatment of acute myeloid leukemia characterized by the presence of a mutant allele of IDH2 and the absence of a mutant allele of NRAS
US10137130B2 (en) 2016-02-26 2018-11-27 Celgene Corporation Methods of treatment of malignancies
BR112019004356A2 (pt) * 2016-09-07 2019-05-28 Agios Pharmaceuticals Inc composições de comprimido

Also Published As

Publication number Publication date
US20220323447A1 (en) 2022-10-13
BR112019004356A2 (pt) 2019-05-28
ZA201901321B (en) 2023-12-20
IL265126A (es) 2019-04-30
JP7487270B2 (ja) 2024-05-20
US11389454B2 (en) 2022-07-19
CA3036053A1 (en) 2018-03-15
US20180064715A1 (en) 2018-03-08
JP2022191265A (ja) 2022-12-27
NZ751112A (en) 2024-03-22
IL265126B2 (en) 2023-12-01
EP3509570A1 (en) 2019-07-17
CO2019002092A2 (es) 2019-05-31
MX2019002697A (es) 2019-10-04
AU2017324844A1 (en) 2019-03-21
AU2017324844B2 (en) 2023-05-11
KR102498693B1 (ko) 2023-02-10
JP2019529534A (ja) 2019-10-17
SG11201901873PA (en) 2019-03-28
WO2018048847A1 (en) 2018-03-15
IL265126B1 (en) 2023-08-01
ECSP19015828A (es) 2019-03-29
KR20190045199A (ko) 2019-05-02
CN109715143A (zh) 2019-05-03

Similar Documents

Publication Publication Date Title
CL2019000573A1 (es) Composiciones para comprimidos.
JOP20200122A1 (ar) مركبات مفيدة لتثبيط cdk7
AR108711A1 (es) Compuestos moduladores de fxr (nr1h4)
CL2017001087A1 (es) Derivados de feniltriazol sustituido con hidroxialquilo y sus usos
EA201791256A1 (ru) Производные хиназолина, применяемые для лечения вич
CO2017002714A2 (es) Ácido 4-(3-fluoro-3-(2-(5,6,7,8-tetrahidro-1,8-naftiridin-2-il)etil)pirrolidin-1-il)-3-(3-(2-metoxietoxi)fenil)butanoico, o una sal del mismo
UY36151A (es) ?una composición farmacéutica que comprende un inhibidor de fosfoinosítido 3-quinasa delta y un corticosteroide?.
PH12016501338A1 (en) Indazole compounds as irak4 inhibitors
AR101995A1 (es) COMPUESTOS ANTAGONISTAS DE INTEGRINA avb6
CL2018001199A1 (es) Composiciones terapéuticas para el tratamiento del virus de inmunodeficiencia humana
CR20160310A (es) Composiciones farmacpeuticas que comprenden azd9291
AR089818A1 (es) Inhibidor de la quinasa que regula la señal de la apoptosis
BR112018011154A2 (pt) dispersões sólidas compreendendo um estimulador de sgc
UY35684A (es) Formulación de inhibidores de la tirosina quinasa de bazo (syk)
CL2018002727A1 (es) Medicina obtenida mediante la combinación de agonista fxr y arb
AR103680A1 (es) Inhibidores selectivos de bace1
AR096543A1 (es) INHIBIDORES DE QUINASA PI3 d Y g SELECTIVOS DUALES
CL2019001337A1 (es) Formulaciones farmacéuticas.
BR112017002060A2 (pt) novo uso
SV2016005313A (es) Derivados de carboxamida
MX2017013875A (es) Ciertos inhibidores de la proteína quinasa.
AR094707A1 (es) Compuesto de quinazolin-4-amina, composición farmacéutica que lo comprende y su uso para el tratamiento de una enfermedad mediada por la quinasa rip2
CL2018001067A1 (es) Compuesto piranodipiridínico.
BR112018074985A2 (pt) composições antibacterianas
NI201800065A (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento de cáncer